USA - NASDAQ:VVOS - US92859E2072 - Common Stock
The current stock price of VVOS is 2.48 USD. In the past month the price decreased by -19.12%. In the past year, price decreased by -3.73%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.4 | 99.03B | ||
| CI | THE CIGNA GROUP | 8.86 | 67.18B | ||
| LH | LABCORP HOLDINGS INC | 16.28 | 21.40B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.25 | 19.92B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 108.63 | 19.63B | ||
| FMS | FRESENIUS MEDICAL CARE-ADR | 13.16 | 15.53B | ||
| GH | GUARDANT HEALTH INC | N/A | 12.15B | ||
| HIMS | HIMS & HERS HEALTH INC | 56.24 | 10.17B | ||
| DVA | DAVITA INC | 12.77 | 8.43B | ||
| CHE | CHEMED CORP | 19.87 | 6.37B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 32.47 | 5.87B | ||
| RDNT | RADNET INC | 214.72 | 5.95B |
Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). The company is headquartered in Littleton, Colorado and currently employs 109 full-time employees. The company went IPO on 2020-12-11. The firm's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The firm's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The firm has sleep testing centers and associated medical sleep practice.
VIVOS THERAPEUTICS INC
7921 Southpark Plaza,, Suite 210
Littleton COLORADO US
Employees: 113
Phone: 18669084867
Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). The company is headquartered in Littleton, Colorado and currently employs 109 full-time employees. The company went IPO on 2020-12-11. The firm's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The firm's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The firm has sleep testing centers and associated medical sleep practice.
The current stock price of VVOS is 2.48 USD. The price decreased by -3.88% in the last trading session.
VVOS does not pay a dividend.
VVOS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
VIVOS THERAPEUTICS INC (VVOS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.68).
VIVOS THERAPEUTICS INC (VVOS) has a market capitalization of 18.60M USD. This makes VVOS a Nano Cap stock.
VIVOS THERAPEUTICS INC (VVOS) will report earnings on 2025-11-12.
ChartMill assigns a fundamental rating of 2 / 10 to VVOS. VVOS has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months VVOS reported a non-GAAP Earnings per Share(EPS) of -1.68. The EPS increased by 75.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -55.01% | ||
| ROE | -312.46% | ||
| Debt/Equity | 1.72 |
8 analysts have analysed VVOS and the average price target is 5.36 USD. This implies a price increase of 115.93% is expected in the next year compared to the current price of 2.48.
For the next year, analysts expect an EPS growth of 36.91% and a revenue growth 15.79% for VVOS